FDA Grants Exclusive Market Status to OSE Immunotherapeutics for Heart Transplant Drug
Nantes, Monday, 27 April 2026.
The FDA has granted OSE Immunotherapeutics lucrative Orphan Drug Designation for its heart transplant treatment, unlocking seven years of potential market exclusivity and significant developmental tax incentives.
A Strategic Partnership Bearing Fruit
The development of pegrizeprument highlights a successful licensing and development model for the biotechnology firm, which maintains operations between Nantes and Paris [1][2]. OSE Immunotherapeutics originally discovered and developed the compound before licensing its global rights to Veloxis Pharmaceuticals, Inc. in April 2021 [1][2]. Under the terms of this agreement, which was finalized 5 years prior to this latest regulatory milestone, Veloxis assumed full responsibility for the global development, manufacturing, and future commercialization of the drug across all transplant indications [1][2].
Market Implications and Corporate Momentum
For investors tracking OSE Immunotherapeutics (ISIN: FR0012127173), these regulatory advancements align with a broader period of corporate momentum [2][3]. The company recently unveiled its strategic plan for the 2026 to 2028 period, focusing on four primary levers for value creation [3]. Market sentiment has shown responsiveness to the company’s scientific progress; for instance, shares recently experienced a notable uptick, closing at 5.01 euros after a 4.81 percent rise on the preceding Wednesday [3].